Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 78.58 Delayed Data As of May 06 |  +0.93 / +1.20%Today’s Change | 71.35 Today|||52-Week Range 131.95 | -10.39% Year-to-Date |
Latest BMRN News | Press Releases
| Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech May 06 / MotleyFool.com - Paid Partner Content | Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript Apr 29 / MotleyFool.com - Paid Partner Content |
| BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision Apr 30 / Zacks.com - Paid Partner Content | BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates Apr 29 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 77.68 |
| Today’s open | 78.00 |
| Day’s range | 77.34 - 79.00 |
| Volume | 780,217 |
| Average volume (3 months) | 1,200,999 |
| Market cap | $14.2B |
Data as of 3:59pm ET, 05/06/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +51.10% |
| Revenue growth (last year) | +9.25% |
| P/E ratio | 18.8 |
| Price/Sales | 9.12 |
| Price/Book | 3.45 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | +4.12 | +2.72% |
| NVAXNovavax Inc | +0.78 | +0.45% |
| TECHBio-Techne Corp | -5.82 | -1.40% |
| EXASExact Sciences Corp | -2.64 | -2.39% |
Data as of 4:57pm ET, 05/06/2021
Financials
| Next reporting date | August 5, 2021 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $1.8B |
| Annual profit (last year) | $859.1M |
| Net profit margin | 46.63% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
